Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents

Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an investigational oral selective inhibitor of nuclear export with low central nervous system penet...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sangmin, Mohan, Sanjay, Knupp, Jessica, Chamoun, Kamal, de Jonge, Adrienne, Yang, Fan, Baloglu, Erkan, Shah, Jatin, Kauffman, Michael G., Shacham, Sharon, Bhatnagar, Bhavana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351096/
https://www.ncbi.nlm.nih.gov/pubmed/35922861
http://dx.doi.org/10.1186/s13045-022-01319-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351096/
https://www.ncbi.nlm.nih.gov/pubmed/35922861
http://dx.doi.org/10.1186/s13045-022-01319-y

Ejemplares similares